Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying JADE101, a drug administered by subcutaneous injection, to evaluate its safety and effectiveness in adults with Immunoglobulin A nephropathy IgAN, a kidney condition. This open-label Phase 2 trial aims to better understand how JADE101 works in this patient group and contributes to ongoing clinical knowledge. The study is sponsored by Jade Biosciences, Inc. Participants will receive JADE101 through subcutaneous injections. All participants receive the same treatment without a comparison group. The study will monitor participants from Day 1 through 100 weeks to assess safety and effects on urine protein levels. There is no placebo or blinding in this trial. During the study, participants will attend scheduled visits and undergo laboratory tests to monitor kidney function and protein levels in urine. Researchers will track any treatment-emergent side effects and changes in urine protein creatinine ratio to evaluate the drugs impact. Participants must comply with treatment plans and contraceptive and lifestyle requirements throughout the trial, which lasts approximately 100 weeks.
Actively Recruiting
Researchers are evaluating the safety and preliminary effectiveness of a drug called DB-1311 combined with BNT327 or DB-1305 in adults with various advanced or metastatic solid tumors. This phase II, open-label study includes participants with types of cancer such as hepatocellular carcinoma, cervical cancer, melanoma, head and neck squamous cell carcinoma, ovarian cancer resistant or sensitive to platinum, non-small cell lung cancer, pancreatic ductal carcinoma, breast cancer, colorectal cancer, and metastatic castration-resistant prostate cancer. The purpose is to find suitable doses and assess treatment responses in these targeted groups. Participants receive intravenous doses of DB-1311 combined with either BNT327 or DB-1305. The trial has two parts Part 1 focuses on dose escalation to establish recommended doses, and Part 2 evaluates treatment effects at these doses across different cancer types. Multiple study arms correspond to different combinations and cancer subtypes, with ongoing treatment until study end or discontinuation. The study is conducted at multiple centers and is randomized but open-label. During the study, participants undergo assessments including tumor measurements based on RECIST criteria, safety monitoring for adverse events, and laboratory tests measuring drug levels and immune responses. Researchers track outcomes like dose limiting toxicities, objective response rates, duration of response, overall survival, progression-free survival, and specific cancer markers such as cancer antigen 125 and prostate-specific antigen. The study may last up to 72 months, with long-term follow-up and safety evaluations throughout.